GlassScriptPhysician profile
Phillip C Scott
NPI 1235125816
$2,678.25
in general payments reported to CMS, 2019-2025
38 companies · $743 in 2025
The $743 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $127 · 2021: $376 · 2022: $320 · 2023: $433 · 2024: $445 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.47 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.63 | 2021-2025 | Vraylar, Ubrelvy, Mavyret |
| Novo Nordisk INC | $287.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.70 | 2020-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.50 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $194.56 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $159.27 | 2019-2024 | Shingrix, Arexvy |
| Pfizer INC. | $109.24 | 2019-2025 | |
| Astellas Pharma US INC | $101.90 | 2019-2025 | Veozah |
| Lundbeck LLC | $100.18 | 2025 | Rexulti |
| Exact Sciences Corporation | $93.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $84.64 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $70.78 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $67.49 | 2019-2022 | |
| Abbott Laboratories | $63.77 | 2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Eisai INC. | $48.35 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.